Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial

Overview of attention for article published in Gynecologic Oncology, April 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 8 news outlets
twitter: 12 X users

guideline: 1 clinical guideline source
podcasts: 1 podcast

Readers on

mendeley: 102 Mendeley

So far, Altmetric has seen 12 X posts from 12 X users, with an upper bound of 14,069 followers.

RT @TeamEndo_MSK: The long awaited feMME trial is out! Assessing pathological response following levonorgestrel intrauterine device in cli…

RT @AndreasObermair: @leitaomd @gynoncjnls @SGO_org @MayoClinic @MayoGynecology @acog These patients’ adverse event rate is considerable, i…

RT @TeamEndo_MSK: The long awaited feMME trial is out! Assessing pathological response following levonorgestrel intrauterine device in cli…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 8 additional X posts.